151 related articles for article (PubMed ID: 21450529)
1. Laquinimod in multiple sclerosis.
Giacomini PS; Bar-Or A
Clin Immunol; 2012 Jan; 142(1):38-43. PubMed ID: 21450529
[TBL] [Abstract][Full Text] [Related]
2. Laquinimod, a new oral autoimmune modulator for the treatment of relapsing-remitting multiple sclerosis.
Tselis A
Curr Opin Investig Drugs; 2010 May; 11(5):577-85. PubMed ID: 20419604
[TBL] [Abstract][Full Text] [Related]
3. Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis.
Jolivel V; Luessi F; Masri J; Kraus SH; Hubo M; Poisa-Beiro L; Klebow S; Paterka M; Yogev N; Tumani H; Furlan R; Siffrin V; Jonuleit H; Zipp F; Waisman A
Brain; 2013 Apr; 136(Pt 4):1048-66. PubMed ID: 23518712
[TBL] [Abstract][Full Text] [Related]
4. Oral laquinimod therapy in relapsing multiple sclerosis.
Preiningerova J
Expert Opin Investig Drugs; 2009 Jul; 18(7):985-9. PubMed ID: 19527103
[TBL] [Abstract][Full Text] [Related]
5. Laquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosis.
Thöne J; Gold R
Expert Opin Drug Metab Toxicol; 2011 Mar; 7(3):365-70. PubMed ID: 21306281
[TBL] [Abstract][Full Text] [Related]
6. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.
Polman C; Barkhof F; Sandberg-Wollheim M; Linde A; Nordle O; Nederman T;
Neurology; 2005 Mar; 64(6):987-91. PubMed ID: 15781813
[TBL] [Abstract][Full Text] [Related]
7. Laquinimod (ABR-215062) for the treatment of relapsing multiple sclerosis.
Constantinescu SE; Constantinescu CS
Expert Rev Clin Pharmacol; 2016; 9(1):49-57. PubMed ID: 26536299
[TBL] [Abstract][Full Text] [Related]
8. Oral laquinimod treatment in multiple sclerosis.
Fernández O
Neurologia; 2011 Mar; 26(2):111-7. PubMed ID: 21163185
[TBL] [Abstract][Full Text] [Related]
9. Fumaric acid and its esters: an emerging treatment for multiple sclerosis with antioxidative mechanism of action.
Gold R; Linker RA; Stangel M
Clin Immunol; 2012 Jan; 142(1):44-8. PubMed ID: 21414846
[TBL] [Abstract][Full Text] [Related]
10. Laquinimod in the treatment of relapsing remitting multiple sclerosis.
Hainke U; Thomas K; Ziemssen T
Expert Opin Drug Metab Toxicol; 2016 Jun; 12(6):701-9. PubMed ID: 27089834
[TBL] [Abstract][Full Text] [Related]
11. FTY720 (fingolimod) for relapsing multiple sclerosis.
Horga A; Montalban X
Expert Rev Neurother; 2008 May; 8(5):699-714. PubMed ID: 18457527
[TBL] [Abstract][Full Text] [Related]
12. Insight into the mechanism of laquinimod action.
Brück W; Wegner C
J Neurol Sci; 2011 Jul; 306(1-2):173-9. PubMed ID: 21429524
[TBL] [Abstract][Full Text] [Related]
13. Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.
Thöne J; Ellrichmann G; Seubert S; Peruga I; Lee DH; Conrad R; Hayardeny L; Comi G; Wiese S; Linker RA; Gold R
Am J Pathol; 2012 Jan; 180(1):267-74. PubMed ID: 22152994
[TBL] [Abstract][Full Text] [Related]
14. Laquinimod, a once-daily oral drug in development for the treatment of relapsing-remitting multiple sclerosis.
Brück W; Zamvil SS
Expert Rev Clin Pharmacol; 2012 May; 5(3):245-56. PubMed ID: 22697588
[TBL] [Abstract][Full Text] [Related]
15. The role of laquinimod in modulation of the immune response in relapsing-remitting multiple sclerosis: Lessons from gene expression signatures.
Zilkha-Falb R; Gurevich M; Hayardeny L; Achiron A
J Neuroimmunol; 2015 Jun; 283():11-6. PubMed ID: 26004150
[TBL] [Abstract][Full Text] [Related]
16. Emerging oral drugs for relapsing-remitting multiple sclerosis.
Gasperini C; Ruggieri S
Expert Opin Emerg Drugs; 2011 Dec; 16(4):697-712. PubMed ID: 22148963
[TBL] [Abstract][Full Text] [Related]
17. Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab.
Klotz L; Meuth SG; Wiendl H
Clin Immunol; 2012 Jan; 142(1):25-30. PubMed ID: 21550857
[TBL] [Abstract][Full Text] [Related]
18. Cladribine: mode of action and implications for treatment of multiple sclerosis.
Leist TP; Weissert R
Clin Neuropharmacol; 2011; 34(1):28-35. PubMed ID: 21242742
[TBL] [Abstract][Full Text] [Related]
19. [Immunomodulatory therapy in multiple sclerosis].
Csépány T; Bereczki D
Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
[TBL] [Abstract][Full Text] [Related]
20. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
